La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Curis a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Curis..

Curis (NASDAQ:CRIS) Azioni, Catena delle Opzioni

Curis

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis Inc

CRISPR Therapeutics AG

CRISM THERAPEUTICS CORP by CRISM THERAPEUTICS CORP

Crism Therapeutics Corp

HC Wainwright &amp; Co. analyst Edward White reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $20 price target.

News

Price Target

Reiteration

Analyst Ratings

CRIS

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $20 Price Target

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(1.70) per share which beat the analyst consensus estimate of $(1.83) by 7.1 percent. This is a 20.19 percent increase over losses of $(2.13) per share from the same period last year.

Earnings

Curis Q3 2024 GAAP EPS $(1.70) Beats $(1.83) Estimate, Cash And Cash Equivalents Of $31.6M Is Expected To Provide Cash Runway Into Mid-2025

AFMD

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Curis to report an earnings per share (EPS) of $-1.84.
Anticipation surrounds Curis's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.36, leading to a 1.21% increase in the share price on the subsequent day.
Here's a look at Curis's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.67</td>
<td>-2.12</td>
<td>-2.11</td>
<td>-2.33</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.03</td>
<td>-2.05</td>
<td>-2.03</td>
<td>-2.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731517418_0.png" alt="eps graph" />
<h3>Performance of Curis Shares</h3>
Shares of Curis were trading at $4.12 as of November 12. Over the last 52-week period, shares are down 34.69%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRIS/earnings">To track all earnings releases for Curis visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Examining the Future: Curis's Earnings Outlook

Curis 13G Filing Shows Thomas A. Satterfield, Jr. Reported A 8.05% Stake In The Co As Of October 30, 2024

HC Wainwright &amp; Co. analyst Edward White maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and lowers the price target from $26 to $20.

HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $20

The unregistered warrants to be issued in the concurrent private placement will have an exercise price of $4.92 per share of common stock, will be exercisable immediately and will expire five years following the issuance date. The combined purchase price for one share of common stock and the associated unregistered warrant is $5.045.

Biotech

Health Care

Financing

Offerings

General

Curis Has Announced A Registered Direct Offering Of 2.39M Shares Priced At-The-Market And A Concurrent Private Placement Of Unregistered Warrants To Purchase Up To An Aggregate Of 2.398M Shares

HC Wainwright &amp; Co. analyst Edward White reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $26 Price Target

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.67) by 21.56 percent. This is a 17.81 percent increase over losses of $(2.47) per share from the same period last year. The company reported quarterly sales of $2.546 million which beat the analyst consensus estimate of $2.064 million by 23.37 percent. This is a 15.89 percent increase over sales of $2.197 million the same period last year.

Earnings Beats

Earnings Misses

Curis Q2 2024 GAAP EPS $(2.03) Misses $(1.67) Estimate, Sales $2.546M Beat $2.064M Estimate

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CNSP

CSBR

MCRB

NNVC

NVAX

RENB

RNAZ

SBFM

SKYE

SMLR

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

Truist Securities analyst Robyn Karnauskas maintains Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Buy and maintains $26 price target.

Truist Securities Maintains Buy on Curis, Maintains $26 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Curis

Data update expands AML dataset from 5 to 30 patients
LEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ongoing TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) AML to be presented at the ASCO and EHA conferences.
This update includes data for 25 new patients in the FLT3 mutation (FLT3m) and U2AF1/SF3B1 Splicing Factor mutation (SFm) cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose (RP2D) of 300 mg BID.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">
Prior
Data
</td>
<td colspan="2" rowspan="1">New Data&#x2A;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FLT3m AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">9</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">12</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">SFm AML</td>
<td colspan="2" rowspan="1">3</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">20</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">adjustment for patients with dual mutation&#x2A;&#x2A;</td>
<td colspan="2" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">5</td>
<td colspan="1" rowspan="1">25</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">30</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;&nbsp; data cut-off as of February 26, 2024 &#x2A;&#x2A;&nbsp; 2 patients had both FLT3m and SFm (dual mutation) &nbsp; &nbsp; 1 patient in the initial group of 5 patients; 1 patient in the new group of 25 additional patients

Curis To Present Updated Data From TakeAim Leukemia Study  At The ASCO And EHA Conferences

Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) reported quarterly losses of $(2.05) per share which beat the analyst consensus estimate of $(2.12) by 3.3 percent. This is a 14.58 percent increase over losses of $(2.40) per share from the same period last year. The company reported quarterly sales of $2.09 million which missed the analyst consensus estimate of $2.40 million by 13.08 percent. This is a 9.19 percent decrease over sales of $2.30 million the same period last year.

Curis Q1 EPS $(2.05) Beats $(2.12) Estimate, Sales $2.09M Miss $2.40M Estimate

As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major overbought players in this sector.
<h3>OncoCyte Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>)</h3>
<ul>
<li>On April 11, Oncocyte announced a $15.8 million private placement of securities priced at-the-market under Nasdaq rules. The company&rsquo;s stock gained around 4% over the past five days and has a <a href="https://www.benzinga.com/quote/OCX">52-week high of $6.80 </a>.</li>
<li>RSI Value: 73.87</li>
<li>OCX Price Action: Shares of OncoCyte rose 1.2% to close at $2.9650 on Thursday.</li>
</ul>
<h3>Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>)</h3>
<ul>
<li>On April 5, Curis reported inducement grants under NASDAQ Listing Rule 5635(c)(4). The company&rsquo;s stock gained around 59% over the past month and <a href="https://www.benzinga.com/quote/CRIS"> has a 52-week high </a> of $17.49.</li>
<li>RSI Value: 75.26</li>
<li>CRIS Price Action: Shares of Curis gained 4.1% to close at $15.90 on Thursday.</li>
</ul>
<h3>Revolution Medicines, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvmd#NASDAQ">RVMD</a>)</h3>
<ul>
<li>On April 9, the company announced the publication of a research paper on RMC-6236 in Cancer Discovery. The company&rsquo;s stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/RVMD"> 52-week high </a> of $38.73.</li>
<li>RSI Value: 72.27</li>
<li>RVMD Price Action: Shares of Revolution Medicines gained 2.5% to close at $37.41 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38215617/fear-greed-index-moves-to-greed-zone-following-ppi-data-nasdaq-record-sharp-gains"> Fear &amp; Greed Index Moves To &#39;Greed&#39; Zone Following PPI Data; Nasdaq record Sharp Gains </a>

Penny Stocks

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

RVMD

Top 3 Health Care Stocks That May Collapse In Q2

<h3>Gainers</h3>
<ul>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. The market value of their outstanding shares is at $80.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares increased by 61.38% to $2.1. The market value of their outstanding shares is at $5.0 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares moved upwards by 38.18% to $2.28. The company's market cap stands at $3.3 million. </li>
<li>Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) stock rose 32.55% to $18.12. The company's market cap stands at $1.1 billion. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares increased by 29.55% to $3.77. The company's market cap stands at $146.7 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares moved upwards by 24.62% to $16.7. The market value of their outstanding shares is at $98.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) stock declined by 80.2% to $3.25 during Thursday's regular session. The company's market cap stands at $11.9 million. </li>
<li>Achilles Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHL#NASDAQ">ACHL</a>) stock decreased by 24.17% to $0.91. The market value of their outstanding shares is at $37.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) shares fell 16.81% to $7.87. The company's market cap stands at $202.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 14.55% to $2.35. The company's market cap stands at $8.5 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares declined by 13.48% to $0.14. The market value of their outstanding shares is at $5.5 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock declined by 12.85% to $2.51. The market value of their outstanding shares is at $48.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHL

BRNS

CADL

CTCX

EFTR

EIGR

Kintara Therapeutics, Inc. - Common Stock

KTRA

MGNX

NOTV

TCBP

12 Health Care Stocks Moving In Thursday's Intraday Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group raised the price target for Ralph Lauren Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rl#NYSE">RL</a>) from $165 to $195. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Ralph Lauren shares jumped 16.8% to close at $171.85 on Thursday. <a href="https://www.benzinga.com/quote/RL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC cut Bunge Global SA (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bg#NYSE">BG</a>) price target from $122 to $105. HSBC analyst Wesley Brooks upgraded the stock from Hold to Buy. Bunge Global shares fell 1.7% to close at $86.50 on Thursday. <a href="https://www.benzinga.com/quote/BG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies boosted the price target for Inotiv, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/notv#NASDAQ">NOTV</a>) from $3 to $11.5. Jefferies analyst David Windley upgraded the stock from Hold to Buy. Inotiv shares gained 16.8% to close at $4.30 on Thursday. <a href="https://www.benzinga.com/quote/NOTV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Everest Group, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eg#NASDAQ">EG</a>) price target from $484 to $402. Wells Fargo analyst Elyse Greenspan downgraded the stock from Overweight to Equal-Weight. Everest Group shares fell 7.7% to close at $354.56 on Thursday. <a href="https://www.benzinga.com/quote/EG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity boosted the price target for Spectrum Brands Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spb#NYSE">SPB</a>) from $83 to $86. Canaccord Genuity analyst Brian McNamara downgraded the stock from Buy to Hold. Spectrum Brands shares rose 7.7% to close at $86.10 on Thursday. <a href="https://www.benzinga.com/quote/SPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup cut the price target for Albemarle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) from $175 to $120. Citigroup analyst Patrick Cunningham downgraded the stock from Buy to Neutral. Albemarle shares fell 0.6% to close at $114.33 on Thursday. <a href="https://www.benzinga.com/quote/ALB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased CyberArk Software Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cybr#NASDAQ">CYBR</a>) price target from $245 to $310. Needham analyst Alex Henderson maintained a Buy rating. CyberArk Software shares gained 7.6% to close at $261.60 on Thursday. <a href="https://www.benzinga.com/quote/CYBR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler boosted Paylocity Holding Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcty#NASDAQ">PCTY</a>) price target from $207 to $210. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Paylocity Holding shares gained 2.1% to close at $171.91 on Thursday. <a href="https://www.benzinga.com/quote/PCTY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed Curis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cris#NASDAQ">CRIS</a>) price target from $51 to $26. HC Wainwright &amp; Co. analyst Edward White maintained a Buy rating. Curis shares rose 13.4% to close at $10.65 on Thursday. <a href="https://www.benzinga.com/quote/CRIS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup boosted Liberty Global Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbtya#NASDAQ">LBTYA</a>) price target from $20 to $24. Citigroup analyst Nayab Amjad upgraded the stock from Neutral to Buy. Liberty Global shares fell 1.1% to close at $19.06 on Thursday. <a href="https://www.benzinga.com/quote/LBTYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37030079/dbv-technologies-and-2-other-stocks-under-2-insiders-are-buying"> DBV Technologies And 2 Other Stocks Under $2 Insiders Are Buying </a>

CYBR

LBTYA

PCTY

CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Curis (CRIS – Research Report), Scholar Rock Holding...

Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)

Curis looks to raise $12.1M in private placement

H.C. Wainwright lowered the firm's price target on Curis (CRIS) to $20 from $26 and keeps a Buy rating on the shares. The firm cites dilution from ...

Curis price target lowered to $20 from $26 at H.C. Wainwright

H.C. Wainwright analyst Edward White reiterated a Buy rating on Curis (CRIS – Research Report) today and set a price target of $20.00. Edward White...

Curis Inc. Gains 'Buy' Rating Amid Financial Stability and Promising Clinical Developments

Curis up 4% on emavusertib data in myelodysplastic syndrome

Curis Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Curis GAAP EPS of -$1.70 beats by $0.17, revenue of $2.93M beats by $0.56M

Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript

Curis Inc. Receives Buy Rating: Strong Financials and Promising Clinical Trial Progress Drive Growth Potential

CVSI

DTEGY

EONGY

KEYUF

KNTNF

MKGAF

NLCP

PAVM

POLA

PVCT

QBTS

SACH

SIEGY

SPCB

SRRK

TVTX

VEON

VISL

WKHS

XNET

Press Releases

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis to Present at Upcoming Healthcare Conference in July

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

Curis Provides Second Quarter 2024 Financial and Operating Update

Curis to Present at Upcoming Healthcare Conferences in September

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

Comments

Curis

Curis (CRIS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO